Nasdaq

Milestone Pharmaceuticals Announces FDA Acceptance of the Company’s Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray

MONTREAL and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) (Milestone) today announced that the U.S. Food and Drug Administration (FDA) has accepted ...
Nasdaq

Milestone Pharmaceuticals Announces New PDUFA Action Date and Extension of $75 Million Royalty Purchase Agreement with RTW Investments

The extension of the PDUFA date to December 13, 2025, indicates that the approval process for CARDAMYST is taking longer than expected, which may suggest unresolved issues with the FDA's initial ...